Spero Therapeutics's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.13.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Spero Therapeutics's EPS without NRI or its related term are showing as below:
During the past 11 years, Spero Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 42.40% per year. The lowest was -18.50% per year. And the median was 14.85% per year.
SPRO's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.8 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Spero Therapeutics's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.13.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.27.
Spero Therapeutics (NAS:SPRO) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Spero Therapeutics EPS without NRI Related Terms
Spero Therapeutics EPS without NRI Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SPRO vs ORMP, PLYX, HRTX: EPS without NRI Comparison
For the Biotechnology subindustry, Spero Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (SPRO) has a EPS without NRI of $0.25 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Spero Therapeutics and its competitors. According to the industry distribution chart, Spero Therapeutics ranks #999999 out of 1176 companies in the Biotechnology industry.
Is Spero Therapeutics' EPS without NRI too high?
Spero Therapeutics' current EPS without NRI is $0.25. The Biotechnology industry median EPS without NRI is 16.80. Spero Therapeutics' value of $0.25 is 98.5% below this industry median. Based on the distribution chart, Spero Therapeutics ranks #999999 out of 1176 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' EPS without NRI compare to ORMP and PLYX?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #999999 out of 1176 companies for EPS without NRI. This places Spero Therapeutics in the lower half of its industry. The industry median EPS without NRI is 16.80. Spero Therapeutics' value of $0.25 is 98.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spero Therapeutics's current EPS without NRI of $0.25 is 98.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Spero Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spero Therapeutics's current EPS without NRI is $0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $2.26 — trading 113.2% above its estimated fair value. The current EPS without NRI is $0.25 and 98.5% below the Biotechnology industry median of 16.80. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current EPS without NRI is $0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $2.26 is trading 113.2% above its estimated GF Value™ of $1.06.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for SPRO:
EPS without NRI: $0.25
GF Value™: $1.06 vs. price of $2.26 (113.2% above fair value)
Industry Position: 98.5% below the Biotechnology median (#999999 of 1176)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score
Get the complete analysis for SPRO
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
